High-dose 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitro sou rea hydrochloride (ACNU) with autologous bone marrow rescue for patients with brain stem tumors.
4 patients with brain stem tumors were treated with high-dose ACNU with autologous bone marrow rescue. Hematologic and nonhematologic toxicities were not profound. There was objective evidence of response in 2 out of the 4. All were alive for 11-21 months from onset. Safe administration of high-dose ACNU with marrow rescue will warrant further control studies to determine its superiority over conventional doses.
D001254:Astrocytoma / Q000628:therapy*; D016026:Bone Marrow Transplantation; D001932:Brain Neoplasms / Q000628:therapy*; D001933:Brain Stem; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D006801:Humans; D007700:Kinetics; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D000091402:Prohibitins; D014182:Transplantation, Autologous
D009607:Nitrosourea Compounds; C000717331:PHB2 protein, human; D000091402:Prohibitins; D015376:Nimustine